LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease )
Also on site :
- Beloved Country Music Star Pays Tribute To Classic Judy Garland Song With 'Somewhere Over Laredo'
- 'DWTS' Derek Hough Celebrated 40th Birthday in the Most 'Incredible' Way
- Attacks by over 100 Ukrainian drones repelled overnight – MOD